
ARA-290 Peptide for Sale
Published by Peptara Labs · Updated · How we research and check our pages
EPO Fragment Studied for Selective Receptor Signaling
ARA-290 peptide from Peptara Labs (peptaralabs.io) is a 10mg research vial of cibinetide, an 11 amino acid piece of erythropoietin designed around its tissue-protection receptor rather than its red-cell signal. A vial costs $63 USD, the ARA-290 Black Friday price: 45% off the regular $115. Its batch certificate of analysis is pending, so no purity figure is claimed yet. On pre-order: Ships as soon as stock arrives. Arrival follows transit. It is sold for research use only.
Black Friday price, 45% off, ends November 30
Flat $35 tracked shipping10mg per vial
Ships as soon as stock arrives
$63 USD
Was $115
Add 2 more, unlock 50%
Vials of any product count together in your cart: 1 to 2 vials 45% off, 3 to 4 vials 50% off, 5 to 9 vials 55% off, 10 or more 60% off. No code is added on top.

Shipping, delivery and certificate status
- Shipping
- Flat $35, tracked worldwide to supported markets
- Delivery
- Ships as soon as stock arrives · After dispatch: 5 to 10 business days
- Included
- Vial · Batch certificate pending · Order support on WhatsApp
Buyer facts
What comes with an ARA-290 research order?
The catalog lists one sealed 10mg vial of lyophilized ARA-290. Its batch certificate is pending. The table lists current price and shipping terms. Published studies describe the molecule, and cannot establish the identity or purity of this batch.
| Detail | Peptara Labs ARA-290 (10mg) | Where to check it |
|---|---|---|
| Vial | 10mg of lyophilized cibinetide powder in one sealed vial | Catalog and order summary |
| Price | $63 USD, the ARA-290 Black Friday price: 45% off the regular $115 | The order panel above |
| Availability | Pre-order. Ships as soon as stock arrives. Arrival follows transit. | The order panel above |
| Certificate | Batch certificate pending. No purity figure is claimed yet. | Certificates of analysis |
| Delivery after dispatch | Ships as soon as stock arrives · After dispatch: 5 to 10 business days | Order summary and shipping details |
| Status | Laboratory research only | Research and regulator ledger below |
Your order includes the vial. Batch certificate pending. Delivery details are confirmed with your order. Order support is available on WhatsApp.
Share or cite this page
Before you buy
What should be checked before buying ARA-290?
A certificate needs to establish identity as well as purity. ARA-290 is a specific 11 amino acid peptide, and its first residue is pyroglutamate. That part of the sequence should be clear in the identity record.
- A mass test should match the named peptide. The reference molecular weight is about 1,257.3 g/mol.
- The names ARA-290 and cibinetide should refer to the same material on the product listing and its certificate. pHBSP is another research name.
- HPLC purity is a separate measurement from identity. The certificate should identify the methods used rather than give a percentage without supporting information.
- A certificate must belong to the supplied batch. No measured mass or purity figure is claimed for this pending batch.
The peptide purity guide explains supplier checks. The certificates page lists published documents and pending status.
The short answer
What is ARA-290?
ARA-290 is cibinetide, an 11 amino acid synthetic peptide based on the water-facing surface of EPO's helix B. EPO is short for erythropoietin, a protein best known for its role in red blood cell production. Researchers used a small part of its shape to study a separate receptor signal.
The design aimed to keep signaling through the EPOR/CD131 tissue-protection receptor while avoiding the EPOR receptor pair that drives red blood cells. That is a design goal supported by receptor and model research. It does not establish a benefit or a safety profile for the research vial sold here.
| Property | Reference identity |
|---|---|
| Other names | Cibinetide, ARA290, pHBSP |
| Length | 11 amino acids |
| Origin | The water-facing surface of EPO helix B |
| Sequence | pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser |
| Short sequence | pGlu-EQLERALNSS |
| Formula | C51H84N16O21 |
| Molecular weight | About 1,257.3 g/mol |
| CAS number | 1208243-50-8 |
Sources: Brines et al., 2008, PNAS (PMID 18676614); Collino et al., 2015, Pharmacology and Therapeutics (PMID 25728128); PubChem CID 91810664, checked October 7, 2026.
The Science
How ARA-290 works in research models
EPO can signal through two different receptor assemblies. One uses two EPOR proteins and drives red blood cell production. The other combines EPOR with CD131, also called the beta common receptor. Researchers call the second assembly the innate repair receptor.
Two receptor assemblies
ARA-290 was designed around EPOR/CD131 rather than the EPOR pair. The original model work examined whether the smaller peptide could separate these EPO signals.
Injury-linked receptor expression
The receptor review describes EPOR/CD131 as usually absent in normal tissue and induced by injury or inflammation. This helps explain why tissue state matters in model experiments.
Short measured persistence
The review reports a plasma half-life of about two minutes, alongside sustained effects in research models. Persistence in plasma and the length of a cell signal are different measurements.
Sources: Brines et al., 2008, PNAS (PMID 18676614); Collino et al., 2015, Pharmacology and Therapeutics (PMID 25728128).
Research areas
Common research areas
Sarcoidosis and small nerve fibers
Small human studies measured symptom scores and corneal nerve fibers. Corneal imaging examines the clear front surface of the eye, and later studies used it as a window onto small nerve fiber changes.
Type 2 diabetes research
A phase 2 study measured neuropathy symptoms, corneal nerve fiber density, HbA1c and lipids. These measures address different questions, and cannot be combined into one claim about benefit.
Diabetic macular edema
A small eye study measured vision, retinal thickness and other eye findings. It found no improvement in its main measures. This negative study belongs in the record alongside the nerve research.
Animal models and emotional processing
Animal work examined stroke, kidney ischemia, retinal edema and nerve trauma. A separate healthy-volunteer study examined emotional processing and found no effect on mood.
Sources: Brines et al., 2008, PNAS (PMID 18676614); Heij et al., 2012, Molecular Medicine (PMID 23168581); Dahan et al., 2013, Molecular Medicine (PMID 24136731); Brines et al., 2015, Molecular Medicine (PMID 25387363); Culver et al., 2017, Investigative Ophthalmology and Visual Science (PMID 28475703); Lois et al., 2020, Journal of Clinical Medicine (PMID 32674280); Cerit et al., 2015, European Neuropsychopharmacology (PMID 26431906).
Comparison
How does ARA-290 compare with EPO, BPC-157 and LL-37?
ARA-290 and EPO share a structural origin. BPC-157 and LL-37 are separate peptides with different research records. A comparison can explain those differences, but there is no direct trial here that ranks them against one another.
| Compound | Origin and signaling | Evidence and limits |
|---|---|---|
| ARA-290 | 11 amino acid EPO-derived peptide designed around EPOR/CD131 | Six small human studies with different populations and measurements; long-term safety unknown |
| EPO | Full protein acting on the red-cell receptor pair and the tissue-protection receptor | Red-cell increases and clotting risk limit the tissue-protection research described in the receptor review |
| BPC-157 | A gastric peptide fragment studied through a separate set of mechanisms | The cited review is mainly animal research; it cannot establish the same evidence as cibinetide's human trials |
| LL-37 | The human cathelicidin with membrane and immune-signaling activity | A different molecule and research record, summarized on its own page |
Does ARA-290 raise red blood cells like EPO?
Its design aims to avoid the EPOR pair that drives red blood cell production. The sarcoidosis pilot recorded no safety concerns in clinical and laboratory checks. That is the supported trial observation; it does not justify a claim that blood counts never change.
Sources: Brines et al., 2008, PNAS (PMID 18676614); Collino et al., 2015, Pharmacology and Therapeutics (PMID 25728128); Heij et al., 2012, Molecular Medicine (PMID 23168581); Dahan et al., 2013, Molecular Medicine (PMID 24136731); Brines et al., 2015, Molecular Medicine (PMID 25387363); Culver et al., 2017, Investigative Ophthalmology and Visual Science (PMID 28475703); Lois et al., 2020, Journal of Clinical Medicine (PMID 32674280); Cerit et al., 2015, European Neuropsychopharmacology (PMID 26431906); Gwyer et al., 2019, Cell and Tissue Research (PMID 30915550); Durr et al., 2006, Biochimica et Biophysica Acta (PMID 16716248).
Evidence
What did the ARA-290 studies measure?
The human record spans sarcoidosis, diabetes, eye disease and healthy volunteers. The cards separate the study population from what the authors reported. Similar words such as nerve symptoms and nerve fiber area refer to different measurements, sometimes from different trials.
2008: EPO-derived peptide design
Model: Animal models of stroke, kidney ischemia, retinal edema and nerve trauma.
Reported: The authors reported tissue-protection findings for helix B peptides in these models. Their design separated EPO receptor signals, which became the basis for later cibinetide research.
2012: sarcoidosis pilot
Model: 22 people with sarcoidosis and small fiber neuropathy symptoms, in a blinded placebo-controlled study.
Reported: Clinical and laboratory checks raised no safety concerns. The authors reported a change in the small fiber symptom screening score versus placebo. Pain and fatigue scores changed equally in both groups.
2013: nerve imaging and symptoms
Model: A blinded placebo-controlled study in sarcoidosis with small nerve fiber loss.
Reported: Researchers measured symptoms, corneal small nerve fiber density and walking performance. The imaging work was separate from the 2012 symptom-score pilot, so those findings belong to different studies.
2015: type 2 diabetes study
Model: A phase 2 study of people with type 2 diabetes and painful neuropathy.
Reported: Researchers measured HbA1c, lipids, a pain questionnaire and corneal nerve fibers. They identified no safety issues in the study. The sample and follow-up were too limited to settle long-term safety.
2015: emotional processing
Model: 36 healthy volunteers in a randomized blinded placebo-controlled study.
Reported: The study found no effect on mood and mixed effects on emotion tasks. The authors said the findings did not clearly support an antidepressant-like profile.
2017: corneal nerve fiber area
Model: 64 people in a phase 2b sarcoidosis study.
Reported: The main measure was corneal nerve fiber area. The authors reported a significant change at one of the three strengths tested. The finding was not consistent across all three groups.
2020: diabetic macular edema
Model: Nine people were recruited and eight completed a phase 2 eye study.
Reported: There was no improvement in vision, retinal thickness or the other main eye measures. The study recorded no serious adverse events and no antibodies. Its authors included developer staff.
The negative findings are part of the evidence. The emotional-processing study found no effect on mood, and the eye study found no improvement in its main measures. In the phase 2b nerve study, the main finding appeared in only one of three tested groups.
What are the reported side effects?
The published studies reported no safety concerns during their clinical and laboratory checks. The small eye trial recorded no serious adverse events and no antibodies. These observations cover the people and study windows examined. They cannot establish a complete side-effect profile or safety over longer periods.
Sources: Brines et al., 2008, PNAS (PMID 18676614); Heij et al., 2012, Molecular Medicine (PMID 23168581); Dahan et al., 2013, Molecular Medicine (PMID 24136731); Brines et al., 2015, Molecular Medicine (PMID 25387363); Culver et al., 2017, Investigative Ophthalmology and Visual Science (PMID 28475703); Lois et al., 2020, Journal of Clinical Medicine (PMID 32674280); Cerit et al., 2015, European Neuropsychopharmacology (PMID 26431906).
What is not known
What is not known about ARA-290?
A PubMed search on October 7, 2026 found no phase 3 trial under cibinetide, ARA 290 or ARA290. The verified human studies are small, with observation windows too short to establish long-term safety. The receptor design and the short plasma half-life are different questions from sustained safety in people.
Developer staff appear among the authors of several studies, including the eye study. That relationship belongs beside the findings because independent replication matters. The eye study's main measurements were negative, and the emotional study did not clearly support the profile its authors tested.
ARA-290 has no medicine approval. Its absence from the checked FDA compounding safety-risk page and the July 2026 meeting agenda does not establish clearance. The EMA orphan record describes a development designation, whose meaning is set out in the ledger below.
Sources: Collino et al., 2015, Pharmacology and Therapeutics (PMID 25728128); Heij et al., 2012, Molecular Medicine (PMID 23168581); Brines et al., 2015, Molecular Medicine (PMID 25387363); Culver et al., 2017, Investigative Ophthalmology and Visual Science (PMID 28475703); Lois et al., 2020, Journal of Clinical Medicine (PMID 32674280); Cerit et al., 2015, European Neuropsychopharmacology (PMID 26431906); PubMed literature search, October 7, 2026; EMA EU/3/13/1191, checked October 7, 2026; FDA safety-risk list, checked October 7, 2026; FDA advisory meeting page, July 23 to 24, 2026.
Human trial ledger
ARA-290 human trial ledger
This ledger lists all six human studies verified in the October 7, 2026 literature check. It keeps the population, known sample count, observation window and main measures together. Counts not established in the cited summaries are marked rather than filled in.
| Study | Population and size | Observation window and measures | Reported finding or limit |
|---|---|---|---|
| 2012 sarcoidosis pilot | 22 people with small fiber neuropathy symptoms | 4 weeks; small fiber symptom score, pain, fatigue, clinical and laboratory checks | Small fiber score changed versus placebo; pain and fatigue changed equally in both groups; no safety concerns |
| 2013 sarcoidosis study | Small nerve fiber loss; count not stated in the cited summary | 28 days; symptoms, corneal nerve fiber density and a 6-minute walk test | A separate imaging and symptom study, distinct from the 2012 pilot |
| 2015 diabetes phase 2 | Type 2 diabetes with painful neuropathy; count not stated in the cited summary | 28 days plus one month of follow-up; HbA1c, lipids, pain questionnaire and corneal fibers | No safety issues identified within the study; small early trial |
| 2015 healthy-volunteer study | 36 healthy volunteers | Emotional-processing tests one week later; mood and emotion tasks | No effect on mood; mixed emotion findings did not clearly support an antidepressant-like profile |
| 2017 sarcoidosis phase 2b | 64 people | 28 days; corneal nerve fiber area was the main measure | A significant change appeared at one of three strengths tested |
| 2020 eye phase 2 | 9 recruited, 8 completed; diabetic macular edema | 12 weeks; vision, retinal thickness and other eye measures | No improvement in the main eye measures; no serious adverse events or antibodies |
What does the orphan designation mean?
The EU granted orphan designation EU/3/13/1191 to Araim for cibinetide in sarcoidosis on October 7, 2013. The EMA summary also notes a US orphan designation for neuropathic pain due to sarcoidosis. The source for both statements here is the EMA record.
Orphan designation recognizes a development program for a rare condition. It is not approval and does not establish that a product is safe or effective. The designation belongs to the development record, while this storefront lists a laboratory research vial with a pending batch certificate.
Sources: Heij et al., 2012, Molecular Medicine (PMID 23168581); Dahan et al., 2013, Molecular Medicine (PMID 24136731); Brines et al., 2015, Molecular Medicine (PMID 25387363); Culver et al., 2017, Investigative Ophthalmology and Visual Science (PMID 28475703); Lois et al., 2020, Journal of Clinical Medicine (PMID 32674280); Cerit et al., 2015, European Neuropsychopharmacology (PMID 26431906); PubMed literature search, October 7, 2026; EMA EU/3/13/1191, checked October 7, 2026.
Research timeline
How the ARA-290 record was built
Research timeline
How the ARA-290 record was built
Research timeline
How the ARA-290 record was built
2008: peptide design
Animal studies examined peptides based on the helix B surface of EPO.
2012: sarcoidosis pilot
A placebo-controlled study of 22 people tracked small fiber symptoms and safety.
2013: orphan designation
The EU granted cibinetide orphan designation for sarcoidosis. A separate study examined corneal nerve fibers.
2015: two human studies
Separate studies examined diabetes-related neuropathy and emotional processing in healthy volunteers.
2017: phase 2b
A trial of 64 people measured corneal nerve fiber area in sarcoidosis.
2020: eye study
A small diabetic macular edema trial found no improvement in its main eye measures.
Sources: Brines et al., 2008, PNAS (PMID 18676614); Heij et al., 2012, Molecular Medicine (PMID 23168581); Dahan et al., 2013, Molecular Medicine (PMID 24136731); Brines et al., 2015, Molecular Medicine (PMID 25387363); Culver et al., 2017, Investigative Ophthalmology and Visual Science (PMID 28475703); Lois et al., 2020, Journal of Clinical Medicine (PMID 32674280); Cerit et al., 2015, European Neuropsychopharmacology (PMID 26431906); EMA EU/3/13/1191, checked October 7, 2026.
Your Kit
What's Included

$63 USD Was $115 USD
Flat $35 tracked shipping · Ships as soon as stock arrives · Batch certificate pending · Order support on WhatsApp
Black Friday price, 45% off, ends November 30
ARA-290 10mg Vial
10mg per vial
Batch certificate
Batch certificate pending
Delivery
Ships as soon as stock arrives · After dispatch: 5 to 10 business days
Order support
Contact our team about your order or batch certificate.
Your order includes the vial. Batch certificate pending. Delivery details are confirmed with your order. Order support is available on WhatsApp.
Your Research Order
ARA-290 research vial, batch certificate status, delivery and order support.
Batch certificate
Batch certificate pending
Delivery
Ships as soon as stock arrives · After dispatch: 5 to 10 business days
Order support
Contact our team about your order or batch certificate.
Research and citations
Peer-reviewed and regulator sources
- Brines et al., 2008, PNAS (PMID 18676614). EPO-derived peptides and tissue-protection receptor signaling in animal models.
- Collino et al., 2015, Pharmacology and Therapeutics (PMID 25728128). Innate repair receptor biology and ARA-290 half-life review.
- Heij et al., 2012, Molecular Medicine (PMID 23168581). Placebo-controlled sarcoidosis pilot and small fiber symptom measures.
- Dahan et al., 2013, Molecular Medicine (PMID 24136731). Sarcoidosis study of symptoms, corneal nerve fibers and walking performance.
- Brines et al., 2015, Molecular Medicine (PMID 25387363). Type 2 diabetes phase 2 study of nerve fibers, symptoms and metabolic markers.
- Culver et al., 2017, Investigative Ophthalmology and Visual Science (PMID 28475703). Sarcoidosis phase 2b trial with corneal nerve fiber area as the main measure.
- Lois et al., 2020, Journal of Clinical Medicine (PMID 32674280). Diabetic macular edema phase 2 study with negative main eye measures.
- Cerit et al., 2015, European Neuropsychopharmacology (PMID 26431906). Healthy-volunteer study of mood and emotional processing.
- PubMed literature search, October 7, 2026. Search for cibinetide, ARA 290 or ARA290 with phase 3 or phase III found no phase 3 trial.
- PubChem CID 91810664, checked October 7, 2026. Cibinetide identity, sequence, formula and molecular weight.
- EMA EU/3/13/1191, checked October 7, 2026. Cibinetide orphan designation for sarcoidosis and the summary of US orphan status.
- Gwyer et al., 2019, Cell and Tissue Research (PMID 30915550). BPC-157 review for the comparison of separate research records.
- Durr et al., 2006, Biochimica et Biophysica Acta (PMID 16716248). LL-37 as the human cathelicidin family member.
- FDA safety-risk list, checked October 7, 2026. ARA-290 was not listed in this compounding safety-risk page.
- FDA advisory meeting page, July 23 to 24, 2026. ARA-290 was not among the meeting substances.
Explore more
Related guides, comparisons, and compounds studied for related endpoints
Peptide glossary
Plain definitions of peptide and laboratory terms.
Peptide side effects
How to read the safety record of early research compounds.
What are peptides
Peptide classes, origins and research status.
Are peptides safe
The limits of small studies and animal evidence.
BPC-157
A gastric peptide fragment with a separate research record.
LL-37
The human cathelicidin, studied in membrane and immune-signaling models.
Certificates of analysis
Published certificates and pending batch status.
How to verify peptide purity
Identity and purity checks for a research supplier.
FAQ
Buying ARA-290: FAQ
Where can ARA-290 peptide be bought?
Peptara Labs lists ARA-290, also called cibinetide, as a 10mg research vial on this page. The vial is sold for laboratory research only, and its batch certificate remains pending.
How much does ARA-290 cost?
One 10mg research vial costs $63 USD, the ARA-290 Black Friday price: 45% off the regular $115.
When does ARA-290 ship?
Ships as soon as stock arrives. Delivery windows begin after dispatch: 5 to 10 business days.
Is the ARA-290 batch certificate available?
The batch certificate of analysis is pending, so no purity figure is claimed yet. Published certificates and pending status are listed on the certificates page. No certificate publication date is promised for this batch.
What comes with an ARA-290 order?
One sealed 10mg vial of lyophilized ARA-290. Your order includes the vial. Batch certificate pending. Delivery details are confirmed with your order. Order support is available on WhatsApp.
ARA-290 research FAQ
What is ARA-290?
ARA-290, also called cibinetide, is an 11 amino acid peptide copied from one face of erythropoietin, or EPO. It was designed to act on the tissue-protection receptor rather than the receptor that drives red blood cell production.
What is ARA-290 studied for?
Small phase 2 studies measured nerve fiber loss and symptoms in sarcoidosis, neuropathy and metabolic markers in type 2 diabetes, and eye measures in diabetic macular edema. Animal work examined stroke, kidney injury and nerve trauma. The eye trial found no improvement in its main measures.
What side effects did the ARA-290 trials report?
The published trials reported no safety concerns in their clinical and laboratory checks, and the small eye study recorded no serious adverse events. These were small studies with short observation windows. Safety over longer periods remains unknown.
Is ARA-290 the same as cibinetide?
Yes. ARA-290, ARA 290, ARA290 and cibinetide name the same peptide. The research literature also uses pHBSP.
How is ARA-290 different from BPC-157?
ARA-290 comes from EPO and was designed around the EPOR/CD131 receptor. Its record includes six small human studies. BPC-157 is a gastric peptide fragment whose research record is mostly animal work. These are separate molecules with separate evidence.
Is ARA-290 an approved medicine?
No. The EU granted cibinetide orphan designation for sarcoidosis in 2013. The EMA summary also notes US orphan designation for neuropathic pain due to sarcoidosis. Orphan designation is not medicine approval, and the October 7, 2026 PubMed search found no phase 3 trial. Peptara Labs sells the vial for research use only.
Does ARA-290 affect red blood cell counts?
ARA-290 was designed to avoid the EPOR receptor pair that drives red blood cell production. The small sarcoidosis pilot raised no safety concerns in clinical and laboratory checks. That finding does not establish blood-count effects or long-term safety.
What did the sarcoidosis pilot measure?
The 2012 pilot tracked small fiber symptom scores, pain, fatigue and safety in 22 people. The small fiber screening score changed versus placebo, while pain and fatigue changed equally in both groups. Corneal nerve imaging belongs to later separate studies.
Sources: Brines et al., 2008, PNAS (PMID 18676614); Collino et al., 2015, Pharmacology and Therapeutics (PMID 25728128); Heij et al., 2012, Molecular Medicine (PMID 23168581); Dahan et al., 2013, Molecular Medicine (PMID 24136731); Brines et al., 2015, Molecular Medicine (PMID 25387363); Culver et al., 2017, Investigative Ophthalmology and Visual Science (PMID 28475703); Lois et al., 2020, Journal of Clinical Medicine (PMID 32674280); Cerit et al., 2015, European Neuropsychopharmacology (PMID 26431906); PubMed literature search, October 7, 2026; PubChem CID 91810664, checked October 7, 2026; EMA EU/3/13/1191, checked October 7, 2026; Gwyer et al., 2019, Cell and Tissue Research (PMID 30915550).
Order ARA-290, 10mg vial
Order ARA-290. Ships as soon as stock arrives · After dispatch: 5 to 10 business days. Order support on WhatsApp.
Order NowBatch certificate pending · Ships as soon as stock arrives · Order support on WhatsApp